No Increase in Symptoms Toward the End of the Ocrelizumab Infusion Cycle in Patients With Multiple Sclerosis: Symptom Burden on Ocrelizumab: A Longitudinal Study (SymBOLS).

Ilya KisterCheongeun Oh Elizabeth A Douglas Tamar E Bacon Isabella L O'Shea Erica H Parrotta Andrew BouleyEllen LathiJoshua D Katz

Published in: Neurology. Clinical practice (2023)

Our prospective study failed to uncover evidence for the worsening of symptoms with a longer time from OCR infusion. These findings cast doubt on the existence of wearing off as a physiologic phenomenon in OCR-treated patients with MS. The perception of wearing off is likely the result of natural fluctuations in MS symptoms and attribution bias.

Keyphrases

mass spectrometry
multiple sclerosis
ms ms
low dose
sleep quality
physical activity